Macrophage Pharma’s CEO, Søren Bregenholt discusses business strategy and company potential with Scrip

Executive Summary
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.

To read the full article, go on https://bit.ly/34XzHAK